Down syndrome is a serious chromosome abnormality that affects approximately 1 out of every 800 pregnancies. The more you know about assessing its risks, the better prepared you are to provide reliable, often reassuring news to your patients; as early as during the first trimester of pregnancy.
Eurofins NTD, LLC. First Trimester Screen | Fß protocol is the standard of care in first trimester Down syndrome screening. It utilizes advanced immunoassay blood screening and NT ultrasound measurement to enable you to assess your patient’s risk for Down syndrome faster and more reliably, with detection rates as high as 91% at false positive rates as low as 5% (95% detection rate at a 2% false positive when including an optional fetal nasal bone assessment). (References 13,25) The procedures are non-invasive and totally safe, resulting in fewer logistical complications and unnecessary risks to both mother and fetus.
Clinically proven and validated by 23 population-based studies examining over 260,700 pregnant women, including 2 NIH-sponsored studies (BUN and FaSTER), the First Trimester Screen | Fß (NT/, PAPP-A, free beta hCG) protocol is a patented methodology pioneered by Eurofins NTD, LLC., an innovator in prenatal screening since 1976.
DISCLAIMER: Pursuant to applicable federal and/or state laboratory requirements, Eurofins NTD, LLC has established and verified the accuracy and precision of its testing services. Tests are developed and performance characteristics determined by Eurofins NTD, LLC. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health.